60 Degrees Pharmaceuticals expands ARAKODA access via Runway Health telehealth partnership
60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced on April 15, 2026, a strategic partnership with Runway Health to make ARAKODA (tafenoquine) available to U.S. travelers via a dedicated telehealth platform.
This collaboration allows patients to consult with licensed clinicians through the Runway Health website, receive a clinical evaluation for malaria risk, and, if deemed appropriate, obtain a prescription for home delivery before their departure.
ARAKODA is an FDA-approved, broad-spectrum malaria preventive intended for adults aged 18 and older.
As a once-weekly alternative to traditional daily prophylaxis, the medication offers a streamlined regimen for those traveling to malaria-endemic regions.
Following an initial three-day loading phase prior to travel, the once-per-week maintenance dose is designed to improve patient compliance, which remains a significant hurdle in effective malaria prevention.
The integration into Runway Health’s digital storefront reflects a broader shift in travel medicine toward accessible, on-demand healthcare.
More from United States
Apple Q4 revenue grows 12% to $114.5bn as earnings improve
Palantir Q3 revenue skyrockets 96% to $2.31B
Vertex Q3 revenue climbs 12% to $3.44bn as guidance increases
Oracle plans $20bn fundraising as shares fall 6.2%
Axsome Q3 loss beats estimates as revenue reaches $259.7m
Marvell to acquire Lumentum in $115bn AI deal
